In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Advertisement
Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

Podcast: Woodford’s UK Biotech Fallout, Rare Disease Deals and Brexit

Scrip's Kevin Grogan and Andrew McConaghie try out the padded cell/recording studio at Informa HQ in London, giving their take on three hot topics from biopharma and healthcare.

Brexit Rare Diseases

Sofinnova Raises €333m For European Biotech Fund

Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.
Europe Commercial

Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?

Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
United Kingdom Commercial

Lilly Calls Time On UK Neuroscience Research Center

The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.

United Kingdom Companies

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?

BioPharmaceutical Commercial

GSK Puts Faith In Next Gen Respiratory, Real World Studies

A pioneer in the field, can GSK’s investment in real world studies pay off?

International Biologics
See All
Advertisement
UsernamePublicRestriction

Register